Cyclophosphamide-based metronomic chemotherapy: After 10 years of experience, where do we stand and where are we going?, Critical Reviews in Oncology/Hematology, vol.82, issue.1, pp.40-50, 2012. ,
DOI : 10.1016/j.critrevonc.2011.04.009
A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours, British Journal of Cancer, vol.109, issue.10, pp.2574-2582, 2013. ,
DOI : 10.3109/10428194.2012.743657
Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care, British Journal of Cancer, vol.14, issue.8, pp.1207-1219, 2010. ,
DOI : 10.1200/JCO.2005.01.8010
Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations., Proceedings of the National Academy of Sciences, vol.90, issue.20, pp.9552-9558, 1993. ,
DOI : 10.1073/pnas.90.20.9552
Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity, International Journal of Clinical & Laboratory Research, vol.33, issue.1, pp.6-14, 1994. ,
DOI : 10.1212/WNL.39.3.368
Paclitaxel (Taxol), New England Journal of Medicine, vol.332, issue.15, pp.1004-1018 ,
DOI : 10.1056/NEJM199504133321507
The emerging role of paclitaxel in breast cancer therapy, Clin Cancer Res, vol.1, pp.247-56, 1995. ,
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion., Journal of Clinical Oncology, vol.12, issue.12, pp.2654-66, 1994. ,
DOI : 10.1200/JCO.1994.12.12.2654
Phase II Trial of Weekly Single-Agent Paclitaxel in Platinum/Paclitaxel-Refractory Ovarian Cancer, Journal of Clinical Oncology, vol.20, issue.9, pp.2365-2374, 2002. ,
DOI : 10.1200/JCO.2002.09.130
Weekly, high-dose paclitaxel in advanced lung carcinoma, Cancer, vol.346, issue.10, pp.2480-2486, 2003. ,
DOI : 10.1056/NEJMoa011954
Doxifluridine combined with weekly paclitaxel for second-line treatment in patients with gastric cancer resistant to TS-1, International Journal of Clinical Oncology, vol.6, issue.Suppl 16, pp.146-155, 2007. ,
DOI : 10.1038/bjc.1995.114
Measurement and impact of co-morbidity in elderly patients with advanced non-small cell lung cancer treated with chemotherapy. A phase II study of weekly paclitaxel, Acta Oncologica, vol.20, issue.3, pp.367-75, 2007. ,
DOI : 10.1016/S1040-8428(00)00090-1
Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: A multi-center phase II study, Lung Cancer, vol.69, issue.3, pp.319-341, 2010. ,
DOI : 10.1016/j.lungcan.2009.11.021
Weekly Paclitaxel in Elderly Patients (Aged ??? 70 Years) with Advanced Non???Small-Cell Lung Cancer: An Alternative Choice? Results of a Phase II Study, Clinical Lung Cancer, vol.9, issue.5, pp.280-284, 2008. ,
DOI : 10.3816/CLC.2008.n.043
Do Patients With Advanced Urothelial Carcinoma Benefit From Weekly Paclitaxel Chemotherapy? A GETUG Phase II Study, Clinical Genitourinary Cancer, vol.7, issue.2, pp.28-33, 2009. ,
DOI : 10.3816/CGC.2009.n.018
Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer, Anticancer Res, vol.26, pp.777-81, 2006. ,
Weekly paclitaxel as second/third-line treatment in advanced non-small cell lung cancer patients: efficacy and tolerability, Anticancer Res, vol.25, pp.4611-4615, 2005. ,
Phase II Study of Weekly Paclitaxel in Patients with Non-Small Cell Lung Cancer Who Have Failed Previous Treatments, Oncology, vol.66, issue.5, pp.347-52, 2004. ,
DOI : 10.1159/000079481
Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer, Lung Cancer, vol.44, issue.2, pp.231-240, 2004. ,
DOI : 10.1016/j.lungcan.2003.11.006
Second-line weekly paclitaxel in patients with inoperable non-small cell lung cancer who fail combination chemotherapy with cisplatin, Lung Cancer, vol.45, issue.2, pp.227-263, 2004. ,
DOI : 10.1016/j.lungcan.2004.01.011
Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy, Annals of Oncology, vol.14, issue.11, pp.1640-1647, 2003. ,
DOI : 10.1093/annonc/mdg456
Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel, Cancer, vol.2, issue.6, pp.1265-73, 2002. ,
DOI : 10.3816/CLC.2000.n.026
URL : http://onlinelibrary.wiley.com/doi/10.1002/cncr.10835/pdf
A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer, Clin Cancer Res, vol.7, pp.3942-3951, 2001. ,
Weekly paclitaxel after first-line failure in patients with advanced non-smallcell lung cancer: everyday clinical practice in a single Centre. Anti-Cancer Drugs, pp.654-663, 2017. ,
Intravenous 3-weekly paclitaxel and metronomic oral cyclophosphamide in patients with advanced urothelial cancer previously treated with gemcitabine and platinum, Cancer Chemotherapy and Pharmacology, vol.28, issue.11, pp.247-54, 2015. ,
DOI : 10.1200/JCO.2009.25.4599
Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2??? locally advanced breast cancer, Brazilian Journal of Medical and Biological Research, vol.9, issue.5, pp.479-85, 2015. ,
DOI : 10.2217/fon.12.196
Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer, Clinical Breast Cancer, vol.15, issue.4, pp.259-65, 2015. ,
DOI : 10.1016/j.clbc.2015.03.002